Multiple Sclerosis Journal · 2011 · 76 citations · 4 references
Life SciencesImmunologyNeurologyImmunotherapyNeuroimmunologyDisease ProgressionMultiple SclerosisMultiple Sclerosis PharmacotherapyTuberous Sclerosis ComplexFingolimod TherapyMultiple Sclerosis TherapyRelapsing-remitting Multiple Sclerosis TreatmentSphingosine 1-Phosphate Receptor ModulationSphingosine 1-Phosphate Receptor Modulator TherapySphingosine 1-Phosphate Receptor Modulators
Oral fingolimod (Gilenya) is a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes. Fingolimod reduces relapses and delays disability progression in patients with relapsing forms of multiple sclerosis (MS). We report a patient with MS who developed asystole and sustained bradycardia 21 hours after the first dose of fingolimod.
4